ACXP Company Profile and Key Details

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) closed at $1.96 USD, gaining $0.60 (44.81%) from the previous close of $1.35. The stock is currently mid-range between its 52-week high and low $1.33 and $21.00. With a market capitalization of about $3.10 million, Acurx Pharmaceuticals, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-1.16). Key stats such as the average daily volume over the past year has been around 157.13 thousand shares, trading with heavier-than-usual volume. Headquartered in Staten Island, NY, Acurx Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO David Luci, the company employs approximately 4 people and listed since June 25, 2021. Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections.

Short-term trend indicators are bullishly aligned (SMA20 -17.46%, SMA50 -36.18%, SMA200 -69.43%). The stock’s 14-day RSI is 27.12 (weak momentum), while the ATR of 0.2 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -92.19% below its high and over 16.31% above its low. Average 10-day trading volume of 585.45 thousand shares is significantly above the 3-month average of 89.13 thousand, indicating heightened recent market interest.

Acurx Pharmaceuticals, Inc. has 2.55 million shares outstanding. The public float is 1.98 million shares, elevated short interest at 2.91% of float. This equals 73.79 thousand shares. The short ratio is 1.82 days. Institutional investors hold 7.49% of the float. Insiders own 6.17%. LUCI DAVID P holds 49.26 thousand shares, DELUCCIA ROBERT J has 49.26 thousand shares and Scodari Joseph C has 24.63 thousand shares.

Acurx Pharmaceuticals, Inc. generated EPS of -$8.52 over the past year. Five-year average earnings growth is -7.84%. Wall Street analysts project EPS growth of 43.37% annually over the next five years. The latest quarter delivered EPS of -$1,225.73. The next quarter is forecast at -$1.01. Next year's EPS is expected at $15.27. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $31.00 to $12.00. The high target offers 1481.63% upside. The low target suggests 512.24% downside. The mean target is $24.67. This offers 1158.67% upside. Acurx Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 76031.99%. The prior quarter beat by -5.5%. Over the last six quarters, Apple has recorded several small beats. These include 92924.51% in August 09, 2024.

Acurx Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $4.35. This means the shares are trading below this model’s fair value.

Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) shares are flat 2.41% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Acurx Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -0.33. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $16.00, suggesting 716.33% upside. Our AI forecast model points to short-term weakness (-34.18% over two weeks), a medium-term fall (-50.51% over three months), and a longer-term loss (-68.88% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Acurx Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -34.18%, with price expected at $1.29 by March 23, 2026, within a range of $1.14 to $1.44 3-Month Outlook: Projected fall of -50.51%, reaching $0.97 by June 05, 2026, with a range of $0.42 to $1.50. 1-Year Outlook: Projected loss of -68.88%, with price at $0.61 by March 09, 2027, within a range of $0.00 to $0.00.

Acurx Pharmaceuticals, Inc. trades at a P/E ratio of -0.33, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.83 suggesting the stock is closer to book value. The P/FCF stands at -0.38, also above market averages.